UK markets closed
NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,475.92 +268.82 (+1.48%) CRUDE OIL
78.53 +0.42 (+0.54%) GOLD FUTURES
2,311.20 +2.60 (+0.11%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
50,844.31 +62.11 (+0.12%)
Nektar Therapeutics (NKTR)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.6700 |
| Open | 1.7300 |
| Bid | 1.5500 x 1200 |
| Ask | 1.5800 x 1200 |
| Day's range | 1.5500 - 1.7400 |
| 52-week range | 0.4100 - 1.7900 |
| Volume | |
| Avg. volume | 2,629,990 |
| Market cap | 288.29M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
- Zacks
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
© 2024 Yahoo. All rights reserved.